3 Growth Stocks to Invest $1,000 Right Now

Group 1: Nvidia - Nvidia is establishing itself as a leader in the AI infrastructure market, with Q2 fiscal 2026 revenues increasing by 56% year over year to $46.7 billion, primarily driven by data center demand [4] - The company has begun production shipments of its latest AI data center system, the GB300, delivering nearly 1,000 racks per week, which offers significant performance improvements and energy efficiency [5] - Nvidia's networking revenues surged 98% year over year to $7.3 billion, with its Spectrum-X Ethernet solutions achieving an annual run rate exceeding $10 billion [6] - Despite a high valuation of approximately 39.4 times expected forward earnings, Nvidia's strong business model and financials make it an attractive investment [7] Group 2: CrowdStrike - CrowdStrike reported a 21% year-over-year revenue growth to $1.17 billion in Q2 fiscal 2026, with non-GAAP operating income rising 5.7% to $255 million [8] - The company added 220 new Flex customers, bringing the total to 1,000, as businesses shift from legacy cybersecurity solutions to CrowdStrike's Falcon platform [9] - Total annual recurring revenue (ARR) reached $4.66 billion, up 20% year over year, with management expecting a 22% growth in ARR for fiscal 2026 [11] - CrowdStrike's AI-powered solutions, such as the Charlotte SOC analyst, enhance its competitive edge in the cybersecurity market [12] - The stock trades at a high valuation of 135 times expected forward earnings, supported by its leadership in cybersecurity and improving financials [13] Group 3: Eli Lilly - Eli Lilly's revenues increased by 38% year over year to $15.6 billion in Q2, driven by the growth of its diabetes and weight loss medications, Mounjaro and Zepbound [14] - The company accounted for 57% of U.S. prescriptions for incretin mimetics, with a 41% growth in prescriptions overall [15] - Eli Lilly is significantly expanding its production capacity, producing 1.6 times more salable doses of tirzepatide in the first half of 2025 compared to the previous year [16] - The company is advancing its oral GLP-1 agonist, Orforglipron, with regulatory submissions expected by the end of 2025 [17] - Trading at around 24 times expected forward earnings, Eli Lilly's valuation is supported by projected earnings growth of 75.9% to $22.80 in 2025 and 32.8% to $30.40 in 2026 [18]